Ejercicio en miocardiopatías: evaluación, estratificación del riesgo y prescripción clínica actualizada

Miguel Mateo Montañez Soler; Miguel Ángel Santamaría; Alan García Yánez

doi:10.47487/apcyccv.v7i2.579

Authors

Miguel Mateo Montañez Soler Universidad El Bosque, Programa de Especialización en Medicina del Deporte y Actividad física, Bogotá, Colombia. https://orcid.org/0009-0007-4056-4977
Miguel Ángel Santamaría Universidad El Bosque, Programa de Especialización en Medicina del Deporte y Actividad física, Bogotá, Colombia. https://orcid.org/0000-0001-8185-5825
Alan García Yánez Universidad El Bosque, Programa de Especialización en Medicina del Deporte y Actividad física, Bogotá, Colombia. https://orcid.org/0000-0002-1560-5403

DOI:

https://doi.org/10.47487/apcyccv.v7i2.579

Keywords:

Cardiomyopathies, Exercise, Death, Sudden, Cardiac, Risk Assessmen

Abstract

Cardiomyopathies comprise a heterogeneous group of myocardial disorders that may increase the risk of potentially life-threatening arrhythmias, particularly during physical activity. Historically, this risk prompted conservative recommendations, often leading to broad restrictions on exercise participation. However, advances in the understanding of pathophysiological mechanisms, coupled with improved tools for phenotypic assessment, risk stratification, and genetic evaluation, have enabled a more nuanced and individualized approach. This narrative review provides an updated overview of the relationship between exercise and cardiomyopathies, emphasizing clinical, functional, and imaging markers associated with elevated arrhythmic risk. It also summarizes key criteria that guide decisionmaking regarding which patients may safely engage in low-, moderate-, or even high-intensity physical activity. The importance of comprehensive clinical evaluation, shared decision-making, and longitudinal follow-up is highlighted, as these elements allow exercise prescriptions to be tailored to the specific characteristics and evolving risk profile of each patient. Based on current evidence, exercise should no longer be viewed as a universal contraindication; instead, it may serve as a therapeutic adjunct in appropriately selected and well-stratified individuals.

Downloads

Download data is not yet available.

References

Basu J, MacLachlan H, Bhatia R, Alexander H, Cooper R, Sheikh N. Risk stratification and exercise recommendations in cardiomyopathies and channelopathies: a practical guide for the multidisciplinary team. Heart. 2025;111(12):583-92. doi: 10.1136/heartjnl-2024-324318.

Zeppilli P, Biffi A, Cammarano M, Castelletti S, Cavarretta E, Cecchi F, et al. Italian Cardiological Guidelines (COCIS) for Competitive Sport Eligibility in athletes with heart disease: update 2024. Minerva Med. 2024;115(5):533-64. doi: 10.23736/S0026-4806.24.09519-3.

Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(1):17-96. doi: 10.1093/eurheartj/ehaa605.

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(37):3503-626. doi: 10.1093/eurheartj/ehad194.

Lopes TR, Pereira HM, Silva BM. Perceived exertion: Revisiting the history and updating the neurophysiology and the practical applications. Int J Environ Res Public Health. 2022;19(21):14439. doi: 10.3390/ijerph192114439.

Furrer R, Hawley JA, Handschin C. The molecular athlete: exercise physiology from mechanisms to medals. Physiol Rev. 2023;103(3):1693-787. doi: 10.1152/physrev.00017.2022.

Saeidi M, Ravanbod R, Pourgharib-Shahi MH, Navid H, Goosheh B, Baradaran A, et al. The acute effects of 2 different intensities of resistance exercise on autonomic function in heart failure patients: a randomized controlled trial. Anatol J Cardiol. 2023;27(5):266. doi: 10.14744/AnatolJCardiol.2022.2282.

Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-55. doi: 10.1016/S0140-6736(12)60397-3.

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-240. doi: 10.1161/CIR.0000000000000937.

Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, Salberg L, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2023;8(6):595-605. doi: 10.1001/jamacardio.2023.1042.

Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ. How common is hypertrophic cardiomyopathy… really?: disease prevalence revisited 27 years after CARDIA. Int J Cardiol. 2023;382:64-7. doi: 10.1016/j.ijcard.2023.04.005.

Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1703-10. doi: 10.1161/ circulationaha.108.798314.

Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-75. doi: 10.1016/j. jchf.2018.02.010.

Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69(7):761-73. doi: 10.1016/j.jacc.2016.11.063.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-95. doi: 10.1161/circulationaha.113.007094.

Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A, et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. JAMA. 2017;317(13):1349-57. doi: 10.1001/ jama.2017.2503.

Kwon S, Lee HJ, Han KD, Kim DH, Lee SP, Hwang IC, et al. Association of physical activity with all-cause and cardiovascular mortality in 7666 adults with hypertrophic cardiomyopathy (HCM): more physical activity is better. Br J Sports Med. 2021;55(18):1034-40. doi: 10.1136/ bjsports-2020-101987.

Basu J, Nikoletou D, Miles C, MacLachlan H, Parry-Williams G, TilbyJones F, et al. High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial. Eur Heart J. 2025;46(19):1803-15. doi: 10.1093/eurheartj/ehae919.

Basu J, Finocchiaro G, Jayakumar S, Schönfeld J, MacLachlan H, Miles C, et al. Impact of exercise on outcomes and phenotypic expression in athletes with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;80(15):1498-500. doi: 10.1016/j.jacc.2022.08.715.

Pelliccia A, Caselli S, Pelliccia M, Musumeci MB, Lemme E, Di Paolo F, et al. Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study. Br J Sports Med. 2020;54(16):1008-12. doi: 10.1136/bjsports-2019-100890.

Lampert R, Olshansky B, Heidbuchel H, Lawless C, Saarel E, Ackerman M, et al. Safety of sports for athletes with implantable cardioverter-defibrillators: long-term results of a prospective multinational registry. Circulation. 2017;135(23):2310-2. doi: 10.1161/ circulationaha.117.027828.

Aengevaeren VL, Gommans DF, Dieker HJ, Timmermans J, Verheugt FW, Bakker J, et al. Association between lifelong physical activity and disease characteristics in HCM. Med Sci Sports Exerc. 2019;51(10):1995. doi: 10.1249/mss.0000000000002015.

Drezner JA, Malhotra A, Prutkin JM, Papadakis M, Harmon KG, Asif IM, et al. Return to play with hypertrophic cardiomyopathy: are we moving too fast? A critical review. Br J Sports Med. 2021;55(18):1041- 8. doi: 10.1136/bjsports-2020-102921.

Heymans S, Lakdawala NK, Tschoepe C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. The Lancet. 2023;402(10406):998-1011. doi: 10.1016/s0140-6736(23)01241-2.

Millar LM, Fanton Z, Finocchiaro G, Sanchez-Fernandez G, Dhutia H, Malhotra A, et al. Differentiation between athlete’s heart and dilated cardiomyopathy in athletic individuals. Heart. 2020;106(14):1059-65. doi: 10.1136/heartjnl-2019-316147.

Holloway CJ, Dass S, Suttie JJ, Rider OJ, Cox P, Cochlin LE, et al. Exercise training in dilated cardiomyopathy improves rest and stress cardiac function without changes in cardiac high energy phosphate metabolism. Heart. 2012;98(14):1083-90. doi: 10.1136/ heartjnl-2012-302145.

Peterson DF, Kucera K, Thomas LC, Maleszewski J, Siebert D, LopezAnderson M, et al. Aetiology and incidence of sudden cardiac arrest and death in young competitive athletes in the USA: a 4-year prospective study. Br J Sports Med. 2021;55(21):1196-203. doi: 10.1136/bjsports-2020-102666.

Celeghin R, Cipriani A, Bariani R, Marinas MB, Cason M, Bevilacqua M, et al. Filamin-C variant-associated cardiomyopathy: A pooled analysis of individual patient data to evaluate the clinical profile and risk of sudden cardiac death. Heart Rhythm. 2022;19(2):235-43. doi: 10.1016/j.hrthm.2021.09.029.

Zorzi A, Cipriani A, Bariani R, Pilichou K, Corrado D, Bauce B. Role of exercise as a modulating factor in arrhythmogenic cardiomyopathy. Curr Cardiol Rep. 2021;23(6):57. doi: 10.1007/s11886-021-01489-0.

Corrado D, Anastasakis A, Basso C, Bauce B, BlomströmLundqvist C, Bucciarelli-Ducci C, et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. Int J Cardiol. 2024;395:131447. doi: 10.1016/j. ijcard.2023.131447.

Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1):61-72. doi: 10.1056/ nejmra1509267.

Zorzi A, Rigato I, Bauce B, Pilichou K, Basso C, Thiene G, et al. Arrhythmogenic right ventricular cardiomyopathy: risk stratification and indications for defibrillator therapy. Curr Cardiol Rep. 2016;18(6):57. doi: 10.1007/s11886-016-0734-9.

Bariani R, Cipriani A, Rizzo S, Celeghin R, Bueno Marinas M, Giorgi B, et al. ‘Hot phase’clinical presentation in arrhythmogenic cardiomyopathy. Europace. 2021;23(6):907-17. doi: 10.1093/ europace/euaa343.

Finocchiaro G, Papadakis M, Robertus JL, Dhutia H, Steriotis AK, Tome M, et al. Etiology of sudden death in sports: insights from a United Kingdom regional registry. J Am Coll Cardiol. 2016;67(18):2108-15. doi: 10.1016/j.jacc.2016.02.062.

Chorin E, Lampert R, Bijsterveld NR, Knops RE, Wilde AA, Heidbuchel H, et al. Safety of sports for patients with subcutaneous implantable cardioverter defibrillator (SPORT S-ICD): study rationale and protocol. Heart Rhythm O2. 2024;5(3):182-8. doi: 10.1016/j.hroo.2024.01.007.

Jordà P, Bosman LP, Gasperetti A, Mazzanti A, Gourraud JB, Davies B, et al. Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. Eur Heart J. 2022;43(32):3041-52. doi: 10.1093/eurheartj/ehac289.

Bosman LP, Wang W, Lie ØH, Van Lint FH, Rootwelt-Norberg C, Murray B, et al. Integrating exercise into personalized ventricular arrhythmia risk prediction in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2022;15(2):e010221. doi: 10.1161/ CIRCEP.121.010221.

Graziano F, Cipriani A, Balla D, Bondarev S, Marra MP, Bauce B, et al. Evolving spectrum of arrhythmogenic cardiomyopathy: Implications for Sports Cardiology. Clin Cardiol. 2023;46(9):1072-81. doi: 10.1002/ clc.24069.

Jansen J, Marshall PW, Benatar JR, Cross R, Lindbom TK, Kingsley M. Low-intensity resistance exercise in cardiac rehabilitation: a narrative review of mechanistic evidence and clinical implications. J Clin Med. 2024;13(23):7338. doi: 10.3390/jcm13237338.

Yamamoto S, Okamura M, Akashi YJ, Tanaka S, Shimizu M, Tsuchikawa Y, et al. Impact of Long-Term Exercise-Based Cardiac Rehabilitation in Patients With Chronic Heart Failure―A Systematic Review and MetaAnalysis―. Circ J. 2024;88(9):1360-71. doi: 10.1253/circj.cj-23-0820.

Gudmundsdottir HL, Axelsson Raja A, Rossing K, Rasmusen H, Snoer M, Andersen LJ, et al. Exercise training in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction: a randomized clinical trial. Circulation. 2025;151(2):132-44. doi: 10.1161/CIRCULATIONAHA.124.07006.

Cheng P, Zhang X, Si Y, Yin Q, Chen L, Ru Q, et al. Regulatory mechanisms of exercise-induced physiological cardiac hypertrophy: progress and prospects. Front Cardiovasc Med. 2025;12:1657950. doi: 10.3389/fcvm.2025.1657950.

Gray B, Ackerman MJ, Link MS, Lampert R. Vigorous exercise and sports participation in individuals with hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2025;35(2):116-23. doi: 10.1016/j. tcm.2024.09.004.

Vissing CR, Rasmussen TB, Dybro AM, Olesen MS, Pedersen LN, Jensen M, et al. Dilated cardiomyopathy caused by truncating titin variants: long-term outcomes, arrhythmias, response to treatment and sex differences. J Med Genet. 2021;58(12):832-41. doi: 10.1136/ jmedgenet-2020-107178.

Claessen G, De Bosscher R, Janssens K, Young P, Dausin C, Claeys M, et al. Reduced ejection fraction in elite endurance athletes: clinical and genetic overlap with dilated cardiomyopathy. Circulation. 2024;149(18):1405-15. doi: 10.1161/circulationaha.122.063777.

Sorella A, Galanti K, Iezzi L, Gallina S, Mohammed SF, Sekhri N, et al. Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes. 2025;11(2):206-22. doi: 10.1093/ ehjqcco/qcae109.

Tramèr L, Saguner AM, Beltrami FG, James CA, Calkins H, Duru F. Gene-elusive arrhythmogenic cardiomyopathy: Roles of sports, inflammation, and beyond. Heart Rhythm. 2025:S1547- 5271(25)02964-9.. doi: 10.1016/j.hrthm.2025.09.048.

Jean C, Laprérie AL, Guyomarch B, Guédon A, Goudal A, Morio F, et al. Impact of prior exercise practice on disease characteristics in desmoplakin-related arrhythmogenic left ventricular cardiomyopathy. JACC Clin Electrophysiol. 2025;11(9):1923-32. doi: 10.1016/j.jacep.2025.05.007.

Rye EE, Mitchell AM, Santiago CF, La Gerche A, Fatkin D. Exercise in Inherited Cardiomyopathies: Optimizing the Dose-Response Curve. Circ Res. 2025;137(2):316-34. doi: 10.1161/circresaha.125.326396.